ALL >> Business >> View Article
Medication Safety Results Present An Iron-clad Case For Mckesson Cpoe
When we started rolling out a computerized physician order entry (CPOE) system from McKesson at Peninsula Regional Medical Center in 2005, I felt that I had a solid argument for adoption.
As the chief medical information officer, I told physicians and other caregivers that the CPOE system would help us to minimize errors and provide safer care to our patients. Plain and simple, I thought playing the patient safety card would be more than enough to persuade clinicians of the need for change.
One physician, however, said he would not use the system until I could unequivocally prove to him that CPOE could, in fact, improve medical care at Peninsula Regional. In essence, he demanded a well-rounded Aristotelian argument that included not only emotional and logical appeals but concrete data as well.
As a result, I took a methodical approach to decision support — starting with the orthopedic department. I reasoned that these physicians would be most amenable to CPOE because they practice medicine in an evidence-based manner. A "peer-to-peer" training program also helped get physicians, nurses and pharmacists ...
... up to speed quickly.
Most important, we leveraged key interdisciplinary teams — one focusing on anticoagulants and the other on narcotic medications. Focusing our CPOE efforts on use of these medications would help the hospital achieve some significant patient safety wins and reduce some of the dangers associated with high-risk medications.
By using CPOE with high-risk medications, we've been able to:
1. Eliminate concurrent orders of heparin and lovenox, a combination that results in potentially
dangerous complications. The two medications were ordered concurrently three times
between January and June of 2009, but were prevented when a CPOE order that stops
concurrent orders was put into play.
2. Reduce the number of patients with elevated INR (international normalized ratio) for blood
clotting time from greater than 20% to about 10% in a one-year period.
3. Increase compliance with an accepted heparin protocol by 60%, greatly improving
anticoagulation management.
4. Achieve a 19% reduction in adverse drug reactions with dilaudid, a highly overused and
potentially dangerous narcotic medication.
These results have made it possible to convince the naysayers - such as the physician who resisted our initial efforts - that CPOE is worth it. We now operate with 85% CPOE adoption. Instead of spending time trying to persuade clinicians to adopt CPOE, I am working to keep up with the demand for CPOE-driven decision support.
For a complete version of this article, or to learn more about medication safety or CPOE, visit McKesson online.
Add Comment
Business Articles
1. Top Bearing Company Delivering Reliable Performance For Trucks And Industrial ApplicationsAuthor: Bee Overseas
2. Choosing The Right Garden Fencing And Driveway Gates For Your Uk Home
Author: Vikram Kumar
3. The Castle Has No Walls: Why Enterprise Security Must Move Beyond The Perimeter
Author: Robert
4. How Koel Colours Is Shaping The Future Of Cosmetic Pigments In 2026
Author: koel
5. Loyalty Platform Guide: Features, Top Providers & How To Choose The Right One
Author: Ravi Kuamr
6. Vashikaran Astrologer In India | Ram Ratan Shastri Ji
Author: Ram Ratan Shastri Ji.
7. Kitchen Cabinets Marble – A Perfect Blend Of Style And Functionality
Author: mike
8. Why Pharma Brands Need Effective Visual Merchandising In Retail Pharmacies | Brandola
Author: Brandola
9. The Automation Standard: Achieving Zero Tolerance With An Automatic Fly Ash Brick Making Machine
Author: Karmyog India
10. Italian Marble Table – A Symbol Of Luxury And Timeless Elegance
Author: mike
11. The Real Impact Of Back Pain Therapy In Worcestershire
Author: Energize Therapy
12. The Benefits That A Digital Business Card Promises
Author: Angus Carruthers
13. What Factors Contribute Towards The Success Of A Virtual Receptionist?
Author: Eliza Garran
14. Lucintel Forecasts The Global Gate Driver Ic Market To Reach $2,905 Million By 2035
Author: Lucintel LLC
15. Lucintel Forecasts The Global Exosome Research Market To Reach $1,125 Million By 2035
Author: Lucintel LLC






